Abstract:Introduction: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease with high prevalence and mortality. In some acute exacerbations of COPD (AECOPD) in patients with no obvious signs of infection, early antibiotic treatment seems to clinically improve the disease, but more studies are needed to determine the prognostic impact of antibiotic treatment in AECOPD patients with no obvious signs of infection. Purpose: To clarify the impact of antibiotic treatment on the short-term and long-term prognoses of AECOPD patients without obvious signs of infection. Methods: The impact of the two treatment methods on the prognosis of patients was compared at 30, 90, 180, and 360 days after discharge. A multicenter, randomized, parallel-controlled clinical trial was conducted in a department of respiratory and critical care medicine in Central China. All patients met the inclusion criteria for AECOPD, and the patients were randomly assigned to the antibiotic group or the nonantibiotic group at a 1:1 ratio. Patients in the antibiotic group were given moxifloxacin 400 mg/day intravenously for 7 days. Patients in the nonantibiotic group were intravenously injected with the same amount of normal saline as the amount of moxifloxacin given to those in the antibiotic group for 7 days. Results: There were 406 patients in the antibiotic group and 410 patients in the nonantibiotic group. During the short-term and long-term follow-ups, the acute exacerbation frequency, intensive care unit (ICU) treatment rate, mortality, and mMRC and CAT scores were not significantly different between the two groups ( p > 0.05). At the 180- and 360-day follow-ups, the forced expiratory volume in 1 s (FEV1%) and peak expiratory flow (PEF) were not significantly different between the two groups ( p > 0.05). The 30-day readmission rate was significantly lower in the antibiotic group than in the nonantibiotic group ( p < 0.05). The time from discharge to the first acute exacerbation was not significantly different between the two groups ( p > 0.05). The length of the first hospital stay after discharge was significantly lower in the antibiotic group (5.84 days) than in the nonantibiotic group (6.75 days) ( p < 0.05). At the 30-day follow-up, the acute exacerbation frequency, age, C-reactive protein (CRP) level, and sputum viscosity were significantly greater in the nonantibiotic group than in the antibiotic group ( p 62.5 years, with a CRP level >12.56 mg/L or with a sputum viscosity >III, in the nonantibiotic group than in those in the antibiotic group, suggesting that the short-term prognosis was poor. Conclusion: Patients who are >62.5 years of age, have a CRP concentration >12.56 mg/L, or have a sputum viscosity >III without obvious signs of infection should be treated with antibiotics to improve their short-term prognosis. Clinical Trial Registration:: (https://www.chictr.org.cn), (ChiCTR1800018921)

Azithromycin Exposure Induces Transient Microbial Composition Shifts and Decreases the Airway Microbiota Resilience from Outdoor PM 2.5 Stress in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled Trial

The Efficacy and Safety of Azithromycin in Asthma: A Systematic Review

Effect Of The Short-Term Use Of Fluoroquinolone And Beta-Lactam Antibiotics On Mouse Gut Microbiota

Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection

Azithromycin alters spatial and temporal dynamics of airway microbiota in idiopathic pulmonary fibrosis

Study Effect of Azithromycin and Doxycycline in Mucus Producing and Inflammatory Signaling Pathways of Allergic Asthma

Effect of Small Doses of Azithromycin on Pulmonary Ventilation Function and Inflammatory Factors IL-6, IL-13 in Children with Bronchial Asthma

Antibiotic resistance associated with air quality and transferred by airborne particulate matter

Associations of indoor airborne microbiome with lung function: evidence from a randomized, double-blind, crossover study of microbial intervention

Determining the role of a probiotic in the restoration of intestinal microbial balance by molecular and cultural techniques

Ozone Exposure Leads to Changes in Airway Permeability, Microbiota and Metabolome: a Randomised, Double-Blind, Crossover Trial

Gut Microbiome Diversity and Antimicrobial Resistance After a Single Dose of Oral Azithromycin in Children: A Randomized Placebo-Controlled Trial

Minimal impact on the resistome of children in Botswana after azithromycin treatment for acute severe diarrhoeal disease

Dynamic human exposure to airborne bacteria-associated antibiotic resistomes revealed by longitudinal personal monitoring data

Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases

Early-life antibiotic exposure promotes house dust mite-induced allergic airway inflammation by impacting gut microbiota and lung lipid metabolism

Clinical evaluation of azithromycin

The use of antibiotics in the early stage of acute exacerbation of chronic obstructive pulmonary disease in patients without obvious signs of infection: a multicenter, randomized, parallel-controlled study

Azithromycin Inhibits Muscarinic 2 Receptor-Activated and Voltage-Activated Ca2+ Permeant Ion Channels and Ca2+ Sensitization, Relaxing Airway Smooth Muscle Contraction

Effectiveness and safety of azithromycin in the treatment of bronchial asthma:a meta-analy-sis

Association of short-term PM 2.5 exposure with airway innate immune response, microbiota and metabolism alterations in human airways